Sydney, Australia – 10 December 2025: OncoSil Medical Limited (ASX: OSL) (“OncoSil Medical” or “the Company”), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC), is pleased to announce the first commercial patient treatment in the UK using the OncoSil™ device.
The successful treatment was performed on 9 December 2025 at Southampton General Hospital (University Hospital Southampton NHS Foundation Trust), a recognised centre of excellence in oncology. Following the hospital’s participation in the TRIPP-FFX clinical study, this significant milestone marks the transition from clinical trial involvement to the commencement of OncoSil’s commercial operations in the UK.
According to GLOBOCAN, the UK incidence of pancreatic cancer is 11,852 cases, of which OncoSil Medical estimates approximately 3,600 patients would be eligible for treatment per year with the OncoSil™ device as 30% of patients at diagnosis have LAPC.1
Nigel Lange, CEO & Managing Director of OncoSil Medical, said:
" This first commercial treatment in the UK is an important step forward for OncoSil and for patients living with pancreatic cancer. Southampton General Hospital has long been recognised for its excellence in oncology, and we are proud to see the OncoSil™ device now being used in such a leading centre. This milestone marks the beginning of our commercial journey in the UK, which we believe represents an addressable market opportunity of $138 million per annum and reinforces our commitment to expanding access to innovative treatment options for patients around the world.”
Read the full announcement here
About us:
About OncoSil Medical
OncoSil Medical (ASX:OSL) is a global medical device company focused on Interventional Oncology. OncoSil Medical’s mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in addition to chemotherapy.
OncoSil Medical has developed OncoSil™ device for the treatment of unresectable locally advanced pancreatic cancer. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs.
Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year1. Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival.
OncoSil™ has received CE Marking approval, providing marketing authorisation in both the EU and the UK. OncoSil™ is designated as a breakthrough device in both Europe and the United States. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Turkey and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Germany, Greece, Turkey, Portugal, and Israel.
To learn more, please visit: www.oncosil.com
Contact details:
For more information, please contact:
Mr. Nigel Lange
CEO & Managing Director
E: [email protected]
T: +49 30 300 149 3043
Mr. Tim Luscombe & Mr. David Wood
Joint Company Secretaries
E: [email protected]
[email protected]
T: +61 429 707 079 & +61 408 393 670
Media & Investor Enquiries
Ms. Julia Maguire
The Capital Network
Media and Investor Enquiries
E: [email protected]
T: +61 2 8999 3699
